BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33835301)

  • 21. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma.
    Sahni S; Pandya AR; Hadden WJ; Nahm CB; Maloney S; Cook V; Toft JA; Wilkinson-White L; Gill AJ; Samra JS; Dona A; Mittal A
    Int J Cancer; 2021 Mar; 148(6):1508-1518. PubMed ID: 33128797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of activin A and myostatin in patients with pancreatic adenocarcinoma and progressive weight loss.
    Talar-Wojnarowska R; Wozniak M; Borkowska A; Olakowski M; Malecka-Panas E
    J Physiol Pharmacol; 2020 Feb; 71(1):. PubMed ID: 32554845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
    Sun B; Liu X; Gao Y; Li L; Dong Z
    Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.
    Zhou CY; Dong YP; Sun X; Sui X; Zhu H; Zhao YQ; Zhang YY; Mason C; Zhu Q; Han SX
    Cancer Med; 2018 Nov; 7(11):5525-5533. PubMed ID: 30358133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum fibrinogen as a diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
    Chung KH; Lee JC; Lee J; Cho IK; Kim J; Jang W; Yoo BC; Hwang JH
    Pancreatology; 2020 Oct; 20(7):1465-1471. PubMed ID: 32873483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
    Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
    Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening.
    Cremin C; Lee MK; Hong Q; Hoeschen C; Mackenzie A; Dixon K; McCullum M; Nuk J; Kalloger S; Karasinska J; Scudamore C; Kim PTW; Donnellan F; Lam ECS; Lim HJ; Neben CL; Stedden W; Zhou AY; Schaeffer DF; Sun S; Renouf DJ; Schrader KA
    Cancer Med; 2020 Jun; 9(11):4004-4013. PubMed ID: 32255556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
    Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
    Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Large platelet size is associated with poor outcome in patients with metastatic pancreatic cancer.
    Lembeck AL; Posch F; Klocker EV; Szkandera J; Schlick K; Stojakovic T; Kornprat P; Lackner C; Gerger A; Stoeger H; Stotz M; Pichler M
    Clin Chem Lab Med; 2019 Apr; 57(5):740-744. PubMed ID: 30307891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short- and mid-term outcomes of robotic versus laparoscopic distal pancreatosplenectomy for pancreatic ductal adenocarcinoma: A retrospective propensity score-matched study.
    Qu L; Zhiming Z; Xianglong T; Yuanxing G; Yong X; Rong L; Yee LW
    Int J Surg; 2018 Jul; 55():81-86. PubMed ID: 29802919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced mean platelet volume levels predict shorter survival in patients with resectable pancreatic ductal adenocarcinoma and type 2 diabetes.
    Yin JB; Li N; Cui MM; Wang X; Wang RT
    BMC Gastroenterol; 2020 May; 20(1):143. PubMed ID: 32393273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma in the Netherlands: A Nationwide Retrospective Analysis.
    de Rooij T; Tol JA; van Eijck CH; Boerma D; Bonsing BA; Bosscha K; van Dam RM; Dijkgraaf MG; Gerhards MF; van Goor H; van der Harst E; de Hingh IH; Kazemier G; Klaase JM; Molenaar IQ; Patijn GA; van Santvoort HC; Scheepers JJ; van der Schelling GP; Sieders E; Busch OR; Besselink MG;
    Ann Surg Oncol; 2016 Feb; 23(2):585-91. PubMed ID: 26508153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Negative oncologic impact of poor postoperative pain control in left-sided pancreatic cancer.
    Min EK; Chong JU; Hwang HK; Pae SJ; Kang CM; Lee WJ
    World J Gastroenterol; 2017 Jan; 23(4):676-686. PubMed ID: 28216975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Noteworthy prognostic value of phospholipase C delta genes in early stage pancreatic ductal adenocarcinoma patients after pancreaticoduodenectomy and potential molecular mechanisms.
    Zhou X; Liao X; Wang X; Huang K; Yang C; Yu T; Han C; Zhu G; Su H; Han Q; Chen Z; Huang J; Gong Y; Ruan G; Ye X; Peng T
    Cancer Med; 2020 Feb; 9(3):859-871. PubMed ID: 31808619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New Onset of DiabetEs in aSsociation with pancreatic ductal adenocarcinoma (NODES Trial): protocol of a prospective, multicentre observational trial.
    Illés D; Ivány E; Holzinger G; Kosár K; Adam MG; Kamlage B; Zsóri G; Tajti M; Svébis MM; Horváth V; Oláh I; Márta K; Váncsa S; Zádori N; Szentesi A; Czakó B; Hegyi P; Czakó L
    BMJ Open; 2020 Nov; 10(11):e037267. PubMed ID: 33444177
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma.
    Zhao J; Liang Y; Yin Q; Liu S; Wang Q; Tang Y; Cao C
    Braz J Med Biol Res; 2016 Jul; 49(8):. PubMed ID: 27464025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The predictive value and role of stromal tumor-infiltrating lymphocytes in pancreatic ductal adenocarcinoma (PDAC).
    Lianyuan T; Dianrong X; Chunhui Y; Zhaolai M; Bin J
    Cancer Biol Ther; 2018 Apr; 19(4):296-305. PubMed ID: 29313457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thrombospondin-2 is a Highly Specific Diagnostic Marker and is Associated with Prognosis in Pancreatic Cancer.
    Peng HY; Chang MC; Hu CM; Yang HI; Lee WH; Chang YT
    Ann Surg Oncol; 2019 Mar; 26(3):807-814. PubMed ID: 30569296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: a systematic review and meta-analysis.
    Wang JD; Jin K; Chen XY; Lv JQ; Ji KW
    Oncotarget; 2017 Mar; 8(10):16704-16711. PubMed ID: 28053288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased LKB1 predicts poor prognosis in Pancreatic Ductal Adenocarcinoma.
    Yang JY; Jiang SH; Liu DJ; Yang XM; Huo YM; Li J; Hua R; Zhang ZG; Sun YW
    Sci Rep; 2015 May; 5():10575. PubMed ID: 26015068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.